IRIS
SALPINI, ROMINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.497
AS - Asia 2.763
EU - Europa 2.584
SA - Sud America 583
OC - Oceania 86
AF - Africa 74
Continente sconosciuto - Info sul continente non disponibili 11
Totale 24.598
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.406
SG - Singapore 1.429
IT - Italia 661
CN - Cina 490
BR - Brasile 477
HK - Hong Kong 335
DE - Germania 333
IE - Irlanda 242
UA - Ucraina 199
PL - Polonia 196
FR - Francia 187
RU - Federazione Russa 164
SE - Svezia 162
VN - Vietnam 143
GB - Regno Unito 141
KR - Corea 103
FI - Finlandia 90
AU - Australia 80
IN - India 59
ES - Italia 56
CA - Canada 48
JP - Giappone 42
NL - Olanda 42
AR - Argentina 40
CZ - Repubblica Ceca 33
ID - Indonesia 32
MX - Messico 32
AT - Austria 26
BD - Bangladesh 26
TR - Turchia 24
ZA - Sudafrica 22
CO - Colombia 17
BE - Belgio 16
EC - Ecuador 13
MA - Marocco 13
VE - Venezuela 12
PK - Pakistan 11
AE - Emirati Arabi Uniti 9
BG - Bulgaria 8
IQ - Iraq 8
CH - Svizzera 7
CL - Cile 7
NG - Nigeria 7
NP - Nepal 7
PY - Paraguay 7
DZ - Algeria 6
EG - Egitto 6
IR - Iran 6
NZ - Nuova Zelanda 6
PE - Perù 6
UZ - Uzbekistan 6
CM - Camerun 5
EU - Europa 5
KE - Kenya 5
PT - Portogallo 5
RO - Romania 5
A2 - ???statistics.table.value.countryCode.A2??? 4
LT - Lituania 4
HN - Honduras 3
IL - Israele 3
JO - Giordania 3
KZ - Kazakistan 3
LK - Sri Lanka 3
MN - Mongolia 3
PH - Filippine 3
TN - Tunisia 3
BO - Bolivia 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
KG - Kirghizistan 2
MY - Malesia 2
OM - Oman 2
SA - Arabia Saudita 2
SN - Senegal 2
TW - Taiwan 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DK - Danimarca 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
KH - Cambogia 1
NI - Nicaragua 1
PS - Palestinian Territory 1
RS - Serbia 1
ZW - Zimbabwe 1
Totale 24.598
Salva come PNG Salva come JPEG
Città #
Wilmington 4.613
Woodbridge 4.351
Houston 3.878
Singapore 774
Fairfield 737
Chandler 487
Ashburn 435
Ann Arbor 385
Hong Kong 334
Seattle 278
Beijing 275
Cambridge 240
Rome 233
New York 214
Dublin 203
Jacksonville 160
Kraków 157
Santa Clara 139
Medford 136
Los Angeles 129
The Dalles 119
Dearborn 101
Milan 99
Munich 77
Lawrence 65
Buffalo 61
Nuremberg 57
San Diego 56
Dallas 55
Council Bluffs 51
Ho Chi Minh City 48
São Paulo 43
Hanoi 39
Menlo Park 39
London 36
Chicago 34
Moscow 32
Warsaw 31
Zhengzhou 30
Helsinki 29
Melbourne 29
San Francisco 29
Sydney 28
Tokyo 28
La Veta 27
Mülheim 27
Stockholm 25
Redondo Beach 24
Denver 23
Jakarta 23
Creede 22
Palo Alto 22
Brooklyn 21
Chennai 20
Toronto 20
Canberra 19
Poplar 19
San Jose 19
Brno 18
Naples 18
Johannesburg 17
Orem 17
Phoenix 17
Washington 17
Engelhard 16
Guangzhou 16
Lappeenranta 16
Amsterdam 15
Atlanta 15
Boston 15
Brussels 15
Cedarhurst 15
Verona 15
Vienna 15
Olomouc 14
Redwood City 14
Bari 13
Boardman 13
Madrid 13
Seoul 13
Falls Church 12
Mexico City 12
Montreal 12
Brasília 11
Colorado Springs 11
Genoa 11
Shanghai 11
Rio de Janeiro 10
Biên Hòa 9
Manchester 9
Nanjing 9
Pittsburgh 9
Querétaro 9
Ankara 8
Barcelona 8
Belo Horizonte 8
Dhaka 8
Nanchang 8
Norwalk 8
Quito 8
Totale 20.213
Salva come PNG Salva come JPEG
Nome #
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 529
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 481
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 472
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 469
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 467
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 461
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 455
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 454
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 454
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 436
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 436
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 433
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 429
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 425
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 425
Molecular analysis of hepatitis B virus in Bulgaria 421
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 420
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 411
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 410
Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy 402
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 402
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 402
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 400
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 394
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B 393
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 392
HBV, HCV, HDV AND HEV COINFECTIONS IN A COHORT OF HIV POSITIVE PATIENTS IN CAMEROON 391
When phylogenetic analysis complements the epidemiological investigation: a case of HIV-2 infection, Italy 390
Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE) 390
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 385
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. 385
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 384
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 382
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 382
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 377
Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon 364
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 363
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 363
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 359
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. 345
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 336
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 320
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy 271
Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis 256
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 250
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe 247
Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: A case report 239
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 236
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection 229
Different patterns of HIV-1 replication in MACROPHAGES is led by co-receptor usage 206
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir 185
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon 178
Virological reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir-sparing therapy as revealed by highly-sensitive HBV assays. 175
Reliable timescale inference of HBV genotype A origin and phylodynamics 168
Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0 162
Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation 141
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 138
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 134
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 133
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 133
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 128
In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy. 127
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 126
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 118
New markers in monitoring the reactivation of hepatitis B virus infection in immunocompromised hosts 110
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 106
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 106
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control 105
for the Icona Foundation Study Group Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays. 100
A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection. 86
HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection 85
SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021 83
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B 81
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing. 78
Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome. 77
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis 76
Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival 75
null 74
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort 72
An increase in the levels of middle surface antigen characterizes patients developing HBV-driven liver cancer despite prolonged virological suppression 70
Crucial Role of Central Nervous System as a Viral Anatomical Compartment for HIV-1 Infection 69
An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein. 69
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile 68
HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA After Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort 67
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 66
Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression. 64
HIV DNA viral reservoirs in blood and gut-associated lymphoid tissues (GALT): Implications of switch from triple antiretroviral therapy (ART) to 2-drug dolutegravir/lamivudine regimens 64
Amino acid variability of small molecule inhibitors and mAbs target sites in globally circulating RSV strains 64
Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach 64
Hepatitis delta virus (HDV) infection : frequency and outcome in persons living with HIV (PLWH). Data from the ICONA (Italian cohort of naïve for antiretrovirals) cohort 63
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 62
HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV subgenotypes 1 inducing different inflammatory stimuli 62
Kinetics of HBsAg forms in chronic hepatitis delta patients treated with bulevirtide for 48 weeks: correlation with virological response 61
First National Prevalence in Italian Horse Population and Phylogenesis Highlight a Fourth Sub-Type Candidate of Equine Hepacivirus 61
SARS-CoV-2 Mutations and Variants May Muddle the Sensitivity of COVID-19 Diagnostic Assays 60
Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the early phases of chronic infection even in the setting of limited liver damage 58
Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an In Silico Drug Repurposing Approach 58
POTENT ANTIVIRAL ACTIVITY OF NEW GENERATION HIV-1 MATURATION INHIBITORS ON HUMAN PRIMARY CELLS 56
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 56
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs 56
Totale 23.801
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.303
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.303
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.489 0 0 0 0 0 378 472 315 65 105 111 43
2021/2022987 56 59 47 43 34 86 54 35 289 49 27 208
2022/20231.272 120 114 103 139 122 238 87 106 104 16 98 25
2023/2024910 163 26 95 50 90 143 44 17 57 83 21 121
2024/20253.066 110 583 306 213 127 235 336 174 346 218 209 209
2025/20262.708 568 252 556 549 591 192 0 0 0 0 0 0
Totale 25.139